NASDAQ · SLXN
Silexion Therapeutics Corp
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for SLXN: Nov 11, 2026
Silexion Therapeutics Corp Ordinary Shares is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-28.8.
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews- RTTNews · Sep 30, 9:16 AM EDTSilexion Doses First Patient In Phase 2/3 SIL204 Trial For Pancreatic Cancer(RTTNews) – Wednesday, Silexion Therapeutics (SLXN) said the first patient has been dosed in its global Phase 2/3 trial evaluating SIL204 in patients with locally advanced pancreatic cancer (LAPC).
- RTTNews · Sep 29, 2:48 PM EDTBiotech Stocks On The Move – SLXN, SMMT, IOVA, NTHI(RTTNews) – The following biotech stocks recorded notable moves on September 29, 2026, following key developments including positive preclinical data, a strategic investment, higher revenue guidance and encouraging clinical data.
- RTTNews · Sep 28, 12:36 PM EDTSilexion Advances SIL204 With Positive Findings On Systemic Uptake In KRAS-Driven Cancers(RTTNews) – Silexion Therapeutics Corp. (SLXN) announced positive findings from an ongoing translational study evaluating the cellular uptake and gene-silencing mechanism of SIL204, its lead RNA interference (RNAi) candidate for KRAS-driven cancers.
- RTTNews · Sep 10, 2:49 PM EDT5 Biotech Stocks In Spotlight: Tenon Medical, AEON Biopharma, Silexion, Orchestra BioMed & Indaptus(RTTNews) – Several biotech stocks were in focus Thursday, including Tenon Medical following the full repayment of its senior convertible promissory notes; AEON Biopharma after positive forced degradation study results for ABP-450; Silexion Therapeutics ahead of several September
- RTTNews · Sep 4, 9:45 AM EDTSilexion Posts Wider Q2 Loss On Higher SIL-204 Development Costs(RTTNews) – Silexion Therapeutics Corp (SLXN) a clinical-stage biotech company, posted its second quarter financial results, reflecting a wider net loss compared with the prior-year quarter, due to higher operating expenses.
- RTTNews · Aug 12, 4:19 AM EDTSilexion Prices $2.5 Million Offering To Advance SIL204 Clinical Trial, Stock Down(RTTNews) – Silexion Therapeutics Corp. (SLXN) fell 31% in Tuesday's trading after the company announced it has priced a $2.5 million public offering of 3.85 million ordinary shares (or equivalents) and accompanying Series E warrants at $0.65 per share.
- RTTNews · Jun 24, 7:02 AM EDTGerman BfArM Clears Silexion's Phase 2/3 Trial For SIL-204 In Pancreatic Cancer; Stock Down(RTTNews) – Silexion Therapeutics Corporation (SLXN), a clinical-stage biotechnology company, on Tuesday reported German approval of the Phase 2/3 trial for SIL-204 in treating locally advanced pancreatic cancer, from the Federal Institute for Drugs and Medical Devices (Bundesins
- RTTNews · May 26, 2:33 PM EDTSilexion Therapeutics Announces 1-for-10 Reverse Share Split; Stock Down(RTTNews) – Silexion Therapeutics Corp. (SLXN), a clinical-stage biotechnology company in RNA interference (RNAi) therapies for KRAS-driven cancers, announced a 1-for-10 reverse share split of its ordinary shares.
- RTTNews · May 20, 10:19 PM EDTSLXN On Track, IMVT Hits New High, CTEV Eyes Blockbuster Revenue, Big Day Ahead For BDTX(RTTNews) – In today's gainers' list, we cover HCW Biologics, its upcoming catalysts and going concern risks; Silexion's development progress of its lead drug candidate SIL204; Immunovant's encouraging rheumatoid arthritis data; why investors will be closely watching Black Diamon
- RTTNews · May 20, 5:52 AM EDTSilexion Therapeutics Posts Wider Q1 Loss, Advances SIL204 Into Phase 2/3 Trials; Stock Up(RTTNews) – Silexion Therapeutics Corp. (SLXN), a clinical-stage company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, reported first-quarter 2026 financial results and outlined progress in advancing its lead candidate SIL204 into Phase 2/3 clinical develo
- RTTNews · May 15, 10:12 AM EDTSilexion Raises $1M Through Warrants Exercise To Support Corporate Operations; Stock Down(RTTNews) – Silexion Therapeutics Corp. (SLXN) has secured approximately $1 million in gross proceeds following the immediate exercise of previously issued warrants, providing additional working capital as the company advances its RNA interference (RNAi) pipeline targeting KRAS-d
- RTTNews · Nov 26, 7:41 AM ESTSilexion Completes Toxicology Studies For SIL204; Phase 2/3 Pancreatic Cancer Trial To Begin In Q2(RTTNews) – Silexion Therapeutics Corp. (SLXN) announced the successful completion of toxicology studies for SIL204, its next-generation RNA silencing (siRNA) therapy targeting mutated KRAS oncogenes in pancreatic cancer.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Silexion Therapeutics Corp from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.